Investor Update
Released
Released
Announcement PDF
Imagion Biosystems Limited
ASX:IBX
A Breakthrough
in Cancer
Detection
Molecular Magnetic Resonance Imaging
1
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
Imagion
Biosystems MagSense®
Technology
Overview
2
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
Imagion Biosystems Overview
A clinical stage biotechnology company
developing magnetic nanoparticle-based
imaging and drug delivery technologies
3
Molecular Imaging
Lead Product
Targeted nanoparticles have the potential to
improve cancer detection compared to conventional
imaging technologies by adding molecular
specificity and without using radioactivity.
A Phase 1 study for the detection of nodal
metastases in HER2+ Breast Cancer has been
completed. IND for a Phase 2 study in progress.
with a
Drug Delivery
Strong Pipeline
Nanoparticles provide large surface area as carriers
for drugs or can be used as adjuvants in vaccines.
Imaging agents for primary tumor detection in
Prostate Cancer and Ovarian Cancer ready for INDenabling studies and clinical development.
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
An Unmet Need in Cancer
Diagnosis
Screening
Conventional bloodbased tests, like PSA or
CA125, indicate risk of
cancer but are not
diagnostic. Newer
methods like cfDNA or
CTCs improve screening
but require confirmation
before treatment.
4
Investor Deck – ASX:IBX
Imaging
Biopsy
Current imaging
To confirm if a lesion is malignant,
methods can be
biopsies are taken which may be painful
used to identify a
and cause patient complications.
“region of interest”
Subsequent pathology assessment of
or a “suspicious
the tissue sample can take days.
lesion” but can’t
Obtaining tissue for many types of
distinguish between
cancer can be challenging, e.g. lung,
benign or malignant
pancreatic and
lesions.
other deep body organ cancers.
A biopsy and pathology
assessment are required
for most cancers
Copyright October 2024
| ImagionBiosystems.com
Imagion 2.0 - Investor Summary
Corporate and Operational Restructuring Completed
Key Clinical Milestone
Achieved
• Phase 1 study in 13
HER2+ breast cancer
patients completed
• Safety and tolerability
endpoints achieved
• Independent
radiological review
corroborates clinical
utility for nodal detection
Strong Pipeline
•
•
MagSense® HER2 being
readied for IND application for
Phase 2 study to optimize dose
and imaging protocols.
MagSense® imaging agents for
prostate cancer and ovarian
cancer ready for IND-enabling
studies.
Significantly Reduced Operating
Costs
• Eliminated costs of R&D and
Manufacturing obligations in favor of
outsourcing to CROs and CMOs.
• Reduced Management and Board to
essentials to maintain compliance.
• Operating as a “virtual” entity.
• Will fund R&D on a “pay-as-you-go”
basis keeping spending in line with
secured funding
• Cash burn reduced significantly
5
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
2.5
0.09
2
0.08
0.07
1.5
0.06
Millions
New Leadership Team
Share price (A$)
0.1
0.05
1
0.04
0.03
Robert Proulx
Executive Chairman
Robert is a veteran executive of the life
science and medical device sectors and has
led the company through recent
restructuring and recapitalization.
Ward Detwiler
Chief Business Officer
Experienced early-stage technology
executive with a track record of bringing
health technologies including MRI image
software from concept to market.
0.5
0.02
0.01
0
3-Jun-24
3-Jul-24
Volume
3-Aug-24
3-Sep-24
0
3-Oct-24
Share price
Current Issued Capital
6
Melanie Leydin
Non-Executive Director
Brett Mitchell
Non-Executive Director
Melanie is a Chartered Accountant and
a Fellow of the Governance Institute of
Australia with over 30 years of
experience in Accounting and over 20
years in Board positions, currently the
Managing Director of Vistra Australia.
Mr. Mitchell is an experienced corporate
finance executive with over 25 years of
experience in the venture capital and equity
capital markets, leading transactions in the
mining, energy, technology and life
sciences sectors.
Investor Deck – ASX:IBX
Ordinary Shares
35,646,551
Performance Rights
3,275,000
Options (at various prices and dates)
17,607,515
Convertible Notes
4,342,000
Copyright October 2024
| ImagionBiosystems.com
®
MagSense
Technology
A Breakthrough
7
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
IBX Enables Molecular Imaging
8
Conventional Imaging
MagSense®Imaging
Images provide anatomical context but are
not specific and can only identify a region
of interest.
Molecularly targeted imaging agents produce a
distinct image pattern indicating the presence of
a tumor.
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
®
MagSense Molecular Imaging
MagSense® technology aims to transform how medical imaging can detect and diagnose cancer
9
MRI-based
Detection
Specific
Safer
Earlier
Detection
Platform
Technology
Imaging agents work
with exiting MRI systems
widely available in
hospitals around the
globe.
Targeted imaging agents
provide molecular
confirmation of the
presence of cancer not just
a visual assessment of
“suspicious” or abnormal
lesions.
Does not require use of
radioactivity and is a
safe and non-surgical
solution to detect
cancer and reduce the
need for investigative
biopsies.
Would enable earlier
detection of solid tumors
when small and not easily
visible by conventional
methods and/or difficult
and risky to biopsy.
Fits with existing
diagnostic protocols
and can be used for
many cancers as well
as other diseases.
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
MagSense® nanoparticles enable
molecular imaging by producing an
identifiable change in image contrast
when cancer cells are present
How IBX molecular
MRI works
• A targeting moiety (e.g. antibody or peptide)
directs the nanoparticles to the target tissue to ensure
cancer specific detection.
Pre-Dose
Post-Dose
• When present in tissue, the magnetic nanoparticles
create hypointense (dark) contrast in T2 MRI scans.
• The hypointense contrast indicative of the presence
of the targeted MagSense® imaging agent can be
differentiated from normal tissue.
• The change in contrast improves radiological review
when combined with conventional imaging assessments, such as abnormalities in tissue size and shape.
10
Investor Deck – ASX:IBX
Node 1 shows a 27% change in signal intensity
Node 2 shows a 36% change in signal intensity
Copyright October 2024
| ImagionBiosystems.com
$3-4B Market Opportunity
Detection of Nodal Metastases in
HER2+ Breast Cancer
Primary Tumor Detection
in Prostate Cancer
Following primary tumor diagnosis
determine if the cancer has spread to
the lymph nodes.
Following elevated PSA blood test, the
MagSense® PSMA test would identify if
there is a prostate tumor.
Improves on existing standard-of-care
(ultrasound) which is limited to a small
number of nodes and to assessment for
abnormal size/shape only.
Reduces biopsies to only those who test
positive by MagSense® PSMA.
Reduces the need for biopsy and
provides additional context for treatment
and surgical planning.
Augments biopsy procedure by
improving MRI-guided biopsy.
Nodal Testing and Surveillance $200M+/yr
11
Investor Deck – ASX:IBX
Avoids use of radiotracer (PET) testing
for primary diagnosis.
Primary Diagnosis and Surveillance $1B/yr
MagSense® Use Cases
Early Detection of Ovarian Cancer
Following primary tumor diagnosis
determine if the cancer has spread to
the lymph nodes.
Improves on existing standard-of-care
(ultrasound) which is limited to a small
number of nodes and to assessment for
abnormal size/shape only.
Reduces the need for biopsy and
provides additional context for treatment and
surgical planning.
Primary Diagnosis $2B/yr
Copyright October 2024
| ImagionBiosystems.com
Phase 1 Study – Completed
Detection of Nodal Metastases in HER2+ Breast Cancer
• A Phase 1 Study with 13 HER2+ Breast Cancer patients
from 4 sites in Australia. IBI010103
• Imaging agent was safe and well tolerated in all 13 patients
with no AE/SAEs reported related to the imaging agent.
• Blinded review by independent expert panel of radiologists
has corroborated detectable magnetic signature.
• Can improve on ultrasound which is limited to assessment for
abnormal size/shape and could reduce need for SLNB/ALND.
• Next step - IND and multisite Phase 2 study in process.
12
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
MagSense® will Improve Radiological Review
• Radiological assessment is often subjective, with significant inter-operator
Post-Contrast
differences in interpretation.
• Automated software for detection and segmentation of MagSense® tagged
cells will enable:
• Faster, more accurate reads
• Longitudinal tracking/patient monitoring
• Accelerated product adoption
• Numerous companies and universities have existing software models that can be
the basis for our tool.
• Adding automated detection solutions (SaaMD) will improve the diagnostic utility
and increase the NPV.
13
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
Rationale for MagSense® Imaging Agents
Large addressable markets ($B’s), Expanding access, and Improving outcomes
1. There are >50,000 MRI scanners available globally
(5x as many as PET imaging systems).
2. MagSense® imaging agents have long shelf life and can be
stored and supplied by the hospital pharmacy without the costs
and constraints like radiotracers.
3. Biopsies are expensive and invasive. PET imaging uses radioactivity,
and conventional MRI contrast agents (Gadolinium) are non-specific
and not typically used in cancer detection.
4. The health economics of using MagSense® mMRI are favorable
because it fits within the existing clinical workflow, adds value to the
radiologist’s role in patient management and eliminates unnecessary
and costly invasive procedures, such as biopsies.
14
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
Path to Growth and Key Value Catalysts
Clinical Development Plan and Key Milestones
Completed
HER2+
Breast
Cancer
2024 - 2025
IND
Phase 2
Phase 1
Phase 3
Dose and Image Protocol Optimization
Near-Term
Funding
Needs
File IND and initiate
Phase 2 study for HER2
imaging agent
IND
Ovarian
Cancer
Prostate
Cancer
Pre-Clinical
IND-enabling
Phase 1
Phase 2
Human Safety
IND
Pre-Clinical
IND-enabling
Phase 1
Phase 2
Complete IND
enabling studies for
Prostate Cancer and
Ovarian Cancer to
enter clinical phase.
Human Safety
Results in 3 MagSense® Imaging Agents in Clinical
Testing and improved valuation of IBX
15
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
Investor Rationale
16
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
Focus on Strategic Partnering
Sources: (1) JAMA Oncology. 2022.
Medicare Payment Advisory
Commission (MedPAC) and Centers
for Medicare and Medicaid Services
(CMS). Mordor Intelligence. Global
Contrast Media Market
1. Use of contrast media is well established across medical
imaging technologies with molecular imaging being most
dynamic and driving growth.
2. Global cancer incidence continues to rise1 with Screening &
Diagnostic Imaging being one of the fastest growing
healthcare spend sectors as service providers seek ways to
improve determining malignant vs. benign.2
3. MagSense® imaging agents are completely differentiated and fit the
existing medical imaging and contrast media business model.
4. Incumbents continue making attractive deals for
differentiated clinical-stage assets.
• 2024 Hologic acquired Endomagnetics for $300M
17
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
Comparable Transactions
Acquirer
18
Investor Deck – ASX:IBX
Target
Value AUD
Year
Notes
$18M
2024
Strategic investment. Part of $70M
AUD financing transaction.
$310M
2024
$35M revenue at time of transaction.
Breast cancer
$1.6B
2018
Imuno-oncology agent. Acquired
following successful Phase 3.
$328M Est.
2019
All stock acquisition. Estimated
market cap at transaction date.
$3.9B
2018
Acquired in Phase 3, pending FDA
clearance. Radioligand therapy.
Copyright October 2024
| ImagionBiosystems.com
Investment Proposition
1. MagSense® imaging agents have a high probability of receiving
regulatory approval - nearly 100% of contrast media submitted
to the FDA are approved.
2. Progressing through each stage in clinical development
increases the overall probability of success.
3. Since all MagSense® imaging agents work and are detected in
the same way, each successive step for one agent derisks steps
for each additional agent.
Example Probability of Success
at Stage
IND Enabling
24%
Phase 1
28%
Phase 2
30%
Phase 3
59%
Registration
90%
4. Strategic partnerships have higher probability and higher value
at later stages of clinical development.
19
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
info@imagionbio.com | ASX:IBX
20
Investor Deck – ASX:IBX
Copyright October 2024
| ImagionBiosystems.com
Share your feedback
Discover